Bluebird ramps up lentiviral vector production with Durham Facility

By Maggie Lynch

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags Viral vector Manufacturing Gene therapy Cell therapy bluebird bio Clinical supply

Bluebird bio opens its first wholly owned manufacturing facility to produce lentiviral vectors for the company’s investigational gene and cell therapies.

The Durham, North Carolina facility was purchased by bluebird bio in November 2017. Once the facility is completed, the company will have invested $80m (€71m) into the plant equipped with multiple manufacturing suites. Additionally, the site includes warehouse and quality control testing laboratories.

Equipment qualification at the facility is currently underway, with construction already complete. While the facility will begin by producing a clinical and commercial supply of lentiviral vectors needed for the company’s gene and cell therapies, the facility will have the capability to accommodate expansion and manufacturing of commercial drug products.

The 125,000ft2 ​facility currently employees 50 scientists, engineers, manufacturing and operations personal but is estimated to grow to 70 employees by the end of 2019.

Bluebird bio has multi-year agreements with three manufacturing partners in the US and Europe for its lentiviral vector production. Novasep and MilliporeSigma​ in Belgium, Merck KGaA in California, and Brammer Bio in Massachusetts​.

Additionally, bluebird bio is partnered with Lonza, and apceth Biopharma​ to produce drug product for Lenti-D and LentiGlobin.

Bluebird bio did not respond to our request for comment. 

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...